Published in J Cardiovasc Pharmacol on January 01, 1985
[Intensive vitamin D supplementation in the treatment of osteoporosis]. Vnitr Lek (2004) 1.41
Transient hypocalcemia after thyroidectomy. Ann Otol Rhinol Laryngol (1993) 0.87
Antioxidant systems in polymorphonuclear leucocytes of Type 2 diabetes mellitus. Diabet Med (1999) 0.86
Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2-3. Physiol Res (2010) 0.84
Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol (1994) 0.82
Inhibitor(s) of protein synthesis in uremic serum and urine: partial purification and relationship to amino acid transport. Biochem Med (1982) 0.82
Acute effect of hydrochlorothiazide on renal calcium and magnesium handling in postmenopausal women. Physiol Res (1999) 0.82
Carbohydrate metabolism by rat liver slices incubated in serum obtained from uraemic patients. Clin Sci (1969) 0.81
Hippurate participation in the inhibition of glucose utilization in renal failure. Czech Med (1987) 0.81
Serum hippurate and its excretion in conservatively treated and dialysed patients with chronic renal failure. Physiol Res (1991) 0.80
DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan. Kidney Int Suppl (2001) 0.80
Analytical identity of an inhibitor of sodium transport isolated from human serum and urine. Nephron (1985) 0.80
Participation of P-dependent and P-independent glutaminases in rat kidney ammoniagenesis and their modulation by metabolic acidosis, hippurate and insulin. Physiol Res (1998) 0.80
Gluconeogenesis in rat kidney after partial hepatectomy. Physiol Bohemoslov (1971) 0.79
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens (2003) 0.79
Oxidative stress and plasma concentrations of coenzyme Q10, alpha-tocopherol, and beta-carotene in patients with a mild to moderate decrease of kidney function. Nephron (2001) 0.79
Effect of hippurate on glucose utilization in rat kidney cortex slices. Ren Physiol Biochem (1991) 0.79
Does magnesium dysbalance participate in the development of insulin resistance in early stages of renal disease? Physiol Res (2002) 0.78
A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. Methods Find Exp Clin Pharmacol (1996) 0.78
Advanced glycation end-product levels in subtotally nephrectomized rats: beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab (2000) 0.78
[Vitamin D: synthesis, metabolism, regulation, and an assessment of its deficiency in patients with chronic renal disease]. Vnitr Lek (2004) 0.77
Metabolic alterations caused by uraemia. Proc Eur Dial Transplant Assoc (1980) 0.77
Relation between the uptake of glucose and fatty acids by the rat kidney in vivo. Physiol Bohemoslov (1972) 0.77
The role of magnesium deficiency in insulin resistance: an in vitro study. J Hypertens Suppl (1991) 0.77
A procedure for the isolation of an inhibitor of sodium transport from the urine of uraemic patients. Physiol Bohemoslov (1982) 0.77
Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat. Physiol Res (1999) 0.76
Metabolism of palmitate-1-14C in the tissues of rats with streptozotocin diabetes. Physiol Bohemoslov (1981) 0.76
Magnesium deficiency impairs rat soleus muscle glucose utilization and insulin sensitivity. Mater Med Pol (1993) 0.76
Fibrates and renal function. Clin Nephrol (2003) 0.76
Accumulated end products participate in glucose intolerance and insulin resistance in uremia. Nephron (1993) 0.75
[Effect of coenzyme Q10 in patients with kidney diseases]. Cas Lek Cesk (2001) 0.75
[Choice of amoxycilin dosage in impaired renal function (author's transl)]. Bratisl Lek Listy (1978) 0.75
[Prevention of chronic pyelonephritis relapses using metenamine hipuran (author's transl)]. Cas Lek Cesk (1979) 0.75
[Tienilic acid in the treatment of hyperuricemia syndrome (author's transl)]. Bratisl Lek Listy (1981) 0.75
[Uptake and utilization of palmitate 1 14C by some rat tissues in a medium of diabetic serum (author's transl)]. Cesk Gastroenterol Vyz (1978) 0.75
[Repeated administration of furosemide in intensive treatment of edema]. Vnitr Lek (1976) 0.75
Uremic 'toxins' and blood platelet carbohydrate metabolism. Nephron (1981) 0.75
[60th birthday of Prof. T. R. Niederland, M.D., D.Sc]. Vnitr Lek (1975) 0.75
[Rational indications for clinico-biochemical studies]. Cas Lek Cesk (1983) 0.75
[Glycide metabolism disorder in renal failure, therapeutic sequelae]. Vnitr Lek (1975) 0.75
Effect of glucose utilization inhibitor isolated from the serum and urine of patients with chronic renal failure on the free fatty acid metabolism in rat kidney cortex slices. Physiol Bohemoslov (1976) 0.75
[Treatment of schizophrenia using hemodialysis]. Cesk Psychiatr (1985) 0.75
Abnormal carbohydrate metabolism in patients with liver cirrhosis; in vitro study. Diabetologia (1972) 0.75
Abnormal carbohydrate metabolism in uraemia. Some properties of the inhibitor of glucose utilization present in the serum of uraemic patients. Int Urol Nephrol (1971) 0.75
[Cefalotin SPOFA in the treatment of urinary infections]. Bratisl Lek Listy (1983) 0.75
Isolation of an inhibitor responsible for abnormal glucose utilization in liver disease. Acta Diabetol Lat (1975) 0.75
[Acute antihypertensive and diuretic effects of Metipamide VUFB]. Vnitr Lek (1985) 0.75
[Effect of fasting on the free fatty acid metabolism in sections of the kidney cortex of rats (author's transl)]. Cesk Gastroenterol Vyz (1976) 0.75
[Serotonin antagonists in the treatment of hypertension]. Cas Lek Cesk (1984) 0.75
Liver glycogen concentration in patients with chronic uremia. Experientia (1968) 0.75
Influence of inhibitor of glucose utilization on the blood platelet function. Nephron (1983) 0.75
[Use of amiloride in diuretic treatment (author's transl)]. Bratisl Lek Listy (1975) 0.75
[Determination and interpretation of the diuretic equivalence of azosemid and furosemide]. Vnitr Lek (1982) 0.75
[The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program]. Cas Lek Cesk (1983) 0.75
Carbohydrate metabolism in renal medullary slices. Physiol Bohemoslov (1967) 0.75
[Metabolic changes in renal insufficiency]. Z Gesamte Inn Med (1978) 0.75
[Nutritional status of patients before kidney transplantation]. Vnitr Lek (1984) 0.75
Effect of glucose on the utilization of palmitate 1 14C by rat kidney cortex slices. Physiol Bohemoslov (1975) 0.75
[Dihydralazin treatment of hypertension during hemodialysis]. Z Urol Nephrol (1973) 0.75
[Nephrotoxic effects of gentamicin in patients with damaged kidneys (author's transl)]. Bratisl Lek Listy (1979) 0.75
Acute effects of antagonist of S2-receptors. Czech Med (1984) 0.75
Relationship between free fatty acids and glucose uptake by rat kidney cortex slices. Physiol Bohemoslov (1972) 0.75
Pathogenesis of metabolic alterations in renal failure. Czech Med (1984) 0.75
Localization of the inhibition of gluconegenesis in kidney slices by uremic serum. Med Exp Int J Exp Med (1968) 0.75
[Diuretic effects of chlorthalidone]. Vnitr Lek (1979) 0.75
[Cephalotin therapy in renal insufficiency (author's transl)]. Cas Lek Cesk (1976) 0.75
[Mean molecular substance volume in the sera of patients after kidney transplant operation (author's transl)]. Cas Lek Cesk (1977) 0.75
[Effect of the inhibitor of glucose utilization, isolated from serum of patients in uremia, upon morphology and membrane permeability of erythrocytes (author's transl)]. Bratisl Lek Listy (1974) 0.75
[Ketanserin in the treatment of ischemic disease of the lower extremities]. Cas Lek Cesk (1985) 0.75
[Clinical investigation of the sulfonamide diuretic, azosemide (BM 02 001)]. Vnitr Lek (1979) 0.75
Serum and ultradiafiltrate middle molecules in hemodialysed patients. Int Urol Nephrol (1979) 0.75
Erythrocyte transport of middle molecular substances. Proc Eur Dial Transplant Assoc (1981) 0.75
[Use of lactate in chronic uremia]. Vnitr Lek (1969) 0.75
Effect of vitamin D on serum calcium and inorganic phosphorus concentration in intermittently haemodialyzed patients. Int Urol Nephrol (1972) 0.75
[Can the concentration of middle molecular substances in plasma contribute to the assessment of the adequacy of regular dialysis therapy?]. Cas Lek Cesk (1984) 0.75
Plasma middle molecular substances (MMS) in schizophrenic patients. Int J Artif Organs (1979) 0.75
[Uremia and glycide metabolism]. Cesk Fysiol (1973) 0.75
[How long and how often to dialyse patients with chronic renal failure (author's transl)]. Cas Lek Cesk (1977) 0.75
Glucose utilization in muscle during uremia; in vitro study. Clin Chim Acta (1970) 0.75
[Treatment of oedematous conditions in combining amilorid and hydrochlorothiazid (author's transl)]. Bratisl Lek Listy (1976) 0.75
Middle molecular substances in acute renal failure. Int Urol Nephrol (1982) 0.75
Blood level of middle molecular substances during uraemia and haemodialysis. Proc Eur Dial Transplant Assoc (1973) 0.75
[Metabolic changes in chronic kidney failure]. Bratisl Lek Listy (1978) 0.75
[Combination of methyldopa and diuretics in the treatment of hypertensive disease]. Vnitr Lek (1985) 0.75
Erythrocyte glycolysis in uraemia: cynamic balance caused by the opposite action of various factors. Int Urol Nephrol (1974) 0.75
[Evaluation of education of health service laboratory technicians]. Zdrav Prac (1970) 0.75
[Computer diagnosis in internal medicine]. Vnitr Lek (1985) 0.75
[Short-term dialyses using a conventional hemodialyzer]. Z Urol Nephrol (1978) 0.75
Inhibition of glucose utilization in rat diaphragm by the urinary peptides fractionated by high-voltage electrophoresis. Int Urol Nephrol (1973) 0.75
[70th birthday of Prof. Jaroslav Horejsí, M.D., D.Sc., Member Correspondent of the Czechoslovak Academy of Sciences]. Bratisl Lek Listy (1975) 0.75
Pathophysiology of the carbohydrate metabolism in renal insufficiency. Rev Czech Med (1974) 0.75
Release of free fatty acids by the rat kidney. Physiol Bohemoslov (1977) 0.75
[Inhibition of red blood cell glucose utilization in uremia]. Vnitr Lek (1974) 0.75
Effect of vitamin D on serum magnesium concentration in intermittently haemodialyzed patients. Int Urol Nephrol (1972) 0.75
The synthesis of middle molecular substances in rat tissues: in vitro study. Proc Eur Dial Transplant Assoc (1978) 0.75
[Clinicopharmacologic aspects of the effects of serotonin and its blockade]. Bratisl Lek Listy (1985) 0.75
[Modern diagnosis of energy and nitrogen balance in renal insufficiency]. Bratisl Lek Listy (1984) 0.75
[Tienilic acid and its effect on the biological halftime of amoxycillin (author's transl)]. Cas Lek Cesk (1981) 0.75
Ninhydrin-positive substances in serum and urine of patients with chronic uraemia. Clin Chim Acta (1972) 0.75
[Use of ethacrynic acid in the teatment of edematous states]. Bratisl Lek Listy (1973) 0.75